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Abstract 20 
The HOX genes are a highly conserved family of homeodomain-containing 21 
transcription factors that specify cell identity in early development and, subsequently, 22 
in a number of adult processes including hematopoiesis. The dysregulation of HOX 23 
genes is associated with a number of malignancies including acute myeloid leukemia 24 
(AML) and acute lymphoid leukemia (ALL), where they have been shown to support 25 
the immortalization of leukemic cells both as chimeric partners in fusion genes and 26 
when overexpressed in their wild type form. This review covers our current 27 
understanding of the role of HOX genes in normal hematopoiesis, AML and ALL, 28 
with particular emphasis on the similarities and differences of HOX function in these 29 
contexts, their hematopoietic downstream genes targets and implications for therapy.  30 
Keywords: hematopoiesis, human HOX, murine Hox, AML, ALL. 31 
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1 Introduction 41 
Acute myeloid leukemia (AML) is a heterogeneous group of genetically and 42 
phenotypically aggressive disorders where the differentiation of hematopoietic 43 
progenitor cells is blocked, increasing their self-renewal ability and disturbing the 44 
normal regulation of proliferation1. In the UK, AML is the most frequent acute 45 
leukemia in adults, accounting for 77% of cases. The median age at presentation is 69 46 
years and the male: female ratio is about 5: 4 The disease is commonly classified by 47 
either the French-American-British (FAB) system, or that described by the world 48 
health organization (WHO). The former is based on morphology and maturation stage 49 
and classifies AML into eight groups (M0-M7). The latter is also based on 50 
morphology, but also includes immunophenotyping, genetics and clinical 51 
manifestations and classifies AML into four main groups: AML with recurrent 52 
genetic abnormalities, AML with myelodysplasia-related changes, therapy-related 53 
AML and MDS, or AML that does not fit into any of these groups.  Non-random 54 
chromosomal alterations, such as balanced translocations, monosomies, trisomies, 55 
inversion and deletions have been found in the leukemic cells of almost 55% of AML 56 
patients, and until recently they were considered to be the most crucial prognostic 57 
factors for complete remission (CR), likelihood of relapse, and overall survival3,4. 58 
Recent advances in molecular diagnosis have resulted in both gene alterations 59 
and the dysregulation of specific genes becoming increasingly important as prognostic 60 
elements in AML. This has helped to clarify the numerous heterogeneities of AML 61 
subsets, particularly AML subsets showing normal karyotype (NK-AML)5 and 62 
furthered understanding of the molecular mechanisms of leukemogenesis.  63 
 64 
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1.1 Genetic changes in AML  65 
The origin of AML is associated with two distinct genetic changes, referred to 66 
as Class I and Class II. Class I consists of mutations that enhance proliferation signal 67 
transduction pathways and induce the proliferation of hematopoietic stem cells or 68 
precursors and usually affect kinase signaling pathways, such as FLT3, KIT, 69 
NRAS/KRAS and JAK/STAT mutations. Class I mutations take place late and cause 70 
disease progression. Class II mutations target hematopoietic transcription factor genes 71 
leading to a block in myeloid differentiation and conferring the self-renewal ability of 72 
hematopoietic precursors. These mutations take place early and initiate the AML 73 
disease5-7. One of the most affected and mutated transcription factors are homeobox 74 
(HOX) genes.  75 
1.2 HOX Genes 76 
The HOX genes are a family of homeodomain-containing transcription 77 
factors8, initially characterized in Drosophila as master regulators of trunk and tail 78 
development during embryogenesis9. Duplication of the original HOX gene cluster 79 
has given rise to 39 genes in mammals, separated into four clusters known as A, B, C, 80 
and D9-11. These clusters are located on four different chromosomes, HOXA (7p15), 81 
HOXB (17q21), HOXC (12q13), and HOXD (2q31)12. Ancestors of the original gene 82 
in each of the clusters are known as paralogs, and generally they show a high degree 83 
of sequence similarity as well as functional redundancy (Figure 1)13.  84 
   The arrangement of HOX genes into clusters allows for enhancer sharing 85 
which enables a precise spatial and temporal coordination of expression during 86 
development. The relative regulatory dominance also varies between HOX genes, 87 
giving rise to what is often referred to as a 'HOX code'14, and resulting in the 88 
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following distinctive criteria: (1) Temporal distribution. The expression of HOX genes 89 
starts from the 3' end of the cluster and proceeds stepwise towards the 5' end. (2) 90 
Spatial distribution. The 3’ most member of the cluster is expressed with a more 91 
anterior limit than the next member and each subsequent member has a more posterior 92 
limit of expression resulting in an overlapping series of expression domains. (3) 93 
Posterior prevalence.  In each individual cluster, the function of the posterior gene 94 
products is dominant over the more anterior genes13.  95 
1.3 HOX Cofactors 96 
DNA binding site studies suggest that HOX proteins have relatively limited 97 
selectivity and specificity, and they need cofactor interactions in order to increase 98 
both15-17. The most important HOX-cofactors are the three amino acid loop extension 99 
(TALE) proteins, which comprise the pre B cell leukemia (PBX) and myeloid 100 
ectropic insertion site (MEIS) families16,17. These cofactors play crucial roles in 101 
development and hematopoiesis18. For example, Pbx1 null mice die during the 102 
embryonic stage as a result of severe hematopoietic defects19, and Meis1 deficient 103 
mice fail to generate megakaryocytes, exhibit severe hemorrhaging and likewise die 104 
during the embryonic stage20. In zebrafish, Meis1 and Pbx contribute to the 105 
production of erythropoietic cells and the inhibition of myelopoiesis21. Generally, Hox 106 
proteins 1-10 bind to Pbx122, whereas Hox proteins 9-13 bind to Meis123. 107 
2 HOX genes in hematopoiesis 108 
HOX genes are expressed in hematopoietic stem cells and progenitors in a manner 109 
reminiscent of their expression in early development, with lineage and differentiation 110 
stage- restricted patterns. Thus, for example, HOXB3, HOXB4, and HOXA9 are highly 111 
expressed in uncommitted hematopoietic cells, whilst HOXB8 and HOXA10 are 112 
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expressed in myeloid committed cells. The different HOX clusters also have specific 113 
patterns of lineage restricted expression, whereby HOXA genes are expressed in 114 
myeloid cells, HOXB genes in erythroid cells, and HOXC genes in lymphoid cells. 115 
Intriguingly, the HOXD genes are not expressed in hematopoiesis despite having 116 
similar regulatory regions to the other clusters24-26. Different mammalian CD34+ cell 117 
subpopulations express at least 22 of the 39 HOX genes27. Anterior ''3' end'' HOX 118 
genes (HOX1-6) are highly expressed in the most primitive HSCs. Subsequently, the 119 
anterior HOX genes are down regulated, and posterior "5' end'' HOX genes are 120 
expressed during commitment28. HOX genes are highly expressed in the most 121 
primitive hematopoietic stem cells and progenitors, while their expression is almost 122 
absent in CD34- cells, which are considered differentiated bone marrow cells26,28.  The 123 
analysis of HOX gene expression in human multipotent stem cells and T-cell 124 
precursors showed that HOXA genes are prominently expressed during T-cell 125 
development, in particular the Abd-HOXA genes including HOXA7-HOXA11, with 126 
only HOXB3 and HOXC3 expressed from the other HOX clusters29.  127 
2.1 Gain of function studies 128 
The function of HOX genes in normal hematopoiesis has been widely studied 129 
using gene expression analysis and knock in or knock out studies in hematopoietic 130 
stem cells and early hematopoietic progenitors (Table 1). Generally the 131 
overexpression of a HOX gene leads to an expansion of stem and progenitor cell 132 
populations together with a block on differentiation. Notable examples of this include 133 
the overexpression of murine Hoxb6, which resulted in the expansion of murine HSCs 134 
and myeloid precursors, together with the inhibition of erythropoiesis and 135 
lymphopoiesis30, and overexpression of murine Hoxb3 that resulted in several 136 
hematological abnormalities, such as a block of B and T cell differentiation as well as 137 
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a delay in myeloid precursor proliferation31. Overexpression of human HOXC4 138 
resulted in expansion of early and committed myeloid and erythroid progenitors32, and 139 
knock in of human HOXA5 caused an increase in the number of myeloid progenitors 140 
and blocked erythroid differentiation33,34. Likewise, overexpression of HOXA10 in 141 
human cord blood or fetal liver CD34+ hematopoietic progenitors resulted in a 142 
significant production of blast cells and myelopoiesis concomitant with a complete 143 
block of erythroid differentiation and a severe reduction in B-cell development35. 144 
Other HOX genes are required for the maintenance of progenitor or stem cell status 145 
and promote their proliferation, especially HOXA9 and HOXB4. The former is the 146 
most preferentially expressed HOX gene in human CD34+ hematopoietic stem cells 147 
and early hematopoietic progenitors and is subsequently down regulated during 148 
differentiation. Murine Hoxa9 overexpression enhances HSC expansion and myeloid 149 
progenitor proliferation and, with a long latency, leads to leukemia36,37. In contrast to 150 
myeloid progenitors, Hoxa9 overexpression resulted in a partial inhibition of pre-B 151 
cell differentiation, but did not affect T-cell development37. Hoxb4 is also highly 152 
expressed in hematopoietic stem cells and down regulated during differentiation26,28. 153 
Its overexpression in murine and human cell lines results in a remarkable expansion 154 
of HSCs in vivo and in vitro without resulting in leukemia or lineage disturbances38,39. 155 
Indeed, the self-renewal ability of Hoxb4-transduced HSCs is 20-50 fold greater than 156 
untreated cells, and can be increased still further by knocking down Pbx140,41.  157 
2.2 Loss of function studies  158 
In addition to the knock-in and overexpression approaches described above, 159 
knock down and deletion studies in murine models and cell lines have also been used 160 
to evaluate the role of HOX genes in hematopoiesis. However, due to the functional 161 
redundancy of HOX genes, the results of knock down assays are sometimes difficult 162 
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to interpret and do not always reflect the findings of studies where the gene has been 163 
overexpressed. For example, it has been found that Hoxb4 null mice exhibit a 164 
significant reduction in size and cellularity of hematopoietic organs, such as spleen 165 
and liver, and a slight decrease in HSCs and hematopoietic progenitor number without 166 
a significant disturbance of lineage commitment42,43. Likewise, Hoxb3 null mice 167 
display a notable reduction in B cell progenitors, and a reduction in bone marrow 168 
cellularity, but no significant reduction in B cell numbers in the spleen44.   Hoxb3/b4 -169 
/- mice have a greater reduction in HSCs and hematopoietic progenitors, yet no 170 
difference in hematopoietic cell commitment45. Using quantitative PCR, it has been 171 
demonstrated that fetal liver cells (c-Kit+) of Hoxb4 null mice expressed other Hoxb 172 
genes to a significantly higher level than control cells43.  173 
Bijl and colleagues (2006) found that an individual loss of Hoxb4 or even the 174 
complete loss of the Hoxb cluster (b1-b9) did not affect the ability of murine fetal 175 
liver HSCs to self-renew. The repopulation and differentiation potential were retained, 176 
compared to wild-type control cells. Thus, the Hoxb cluster may not be necessary for 177 
hematopoiesis, with members of the other Hox clusters presumably having largely 178 
duplicate roles. Analysis of Hox gene expression in fetal liver cells (c-Kit+ Hoxb1-179 
Hoxb9-/-), revealed genetic interactions between members of the Hoxa, b and c 180 
clusters, whereby these cells exhibited down regulation of all Hoxa genes, except 181 
Hoxa13,  and up regulation of Hoxc4, Hoxc9 and Hoxc11, also suggesting  functional 182 
redundancy and complex genetic interactions between Hox genes.   183 
An exception to the general prevalence of functional redundancy amongst the 184 
HOX gene family is HOXA9, the most highly expressed HOX family member in 185 
HSCs.  Hoxa9-/- mice showed significant deficiencies in myeloid and lymphoid cells 186 
concomitant with a significant defect in repopulating ability. These deficiencies 187 
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include common myeloid progenitors (CMPs), granulocyte/monocyte precursors 188 
(GMPs), common lymphoid precursors (CLPs) and lymphoid precursors (pro- and 189 
pre-B cells, pro-T cells)47. There is also a corresponding reduction in spleen 190 
cellularity and size. Notably, compared to the entire cluster b deficient fetal liver 191 
HSCs, Hoxa9-/- fetal liver HSCs exhibited a more dramatic defect in repopulating 192 
ability43,47, and HSCs from Hoxa9/b3/b4 null mice had the same repopulating ability 193 
as those from Hoxa9 null mice47. Gene knock-down studies have revealed that some 194 
additional HOX genes are also essential in normal hematopoiesis. Knock down of 195 
HOXA5 led to an increase in erythroid progenitors and a reduction in the number of 196 
myelomonocytic cells33,34, and Hoxa7 null mice showed a reduction in 197 
megakaryocytic/erythroid progenitors (MEP) as well as reticulocytosis and 198 
thrombocytopenia46. Knock out of Hoxb6 resulted in an increase in early erythroid 199 
progenitors in murine bone marrow and fetal liver cells48. Likewise, Hoxc3-/- mice 200 
showed a reduction in late erythroid progenitors without affecting the 201 
hemoglobinization size49, and Hoxc8 deficient mice showed a significant reduction in 202 
erythroid, granulocyte and macrophage colony formation potential50. 203 
 204 
2.3 Upstream regulators of HOX genes 205 
Knock out models of HOX gene upstream regulators have helped to define 206 
their role in normal hematopoiesis. Regulators include transcriptional activators such 207 
as mixed lineage, myeloid lymphoid, leukemia (MLL), and a family of caudal-type 208 
homeobox transcription factors (CDX1, CDX2, and CDX4). The existence of HOX 209 
genes in clusters makes them particularly sensitive to changes in chromosomal 210 
organization, and repressors of HOX transcription include genes that mediate this 211 
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process, most notably members of the polycomb group (PcG)51. These regulators play 212 
crucial roles in normal development and hematopoiesis through the regulation of 213 
HOX genes. A number of studies demonstrated that Mll deficient embryonic bodies 214 
(EB) and Mll conditional knockout mice showed a dramatic reduction in HSCs and 215 
hematopoietic progenitors. Additionally, these EB and the mice exhibited greatly 216 
reduced expression of a number of Hox genes including Hoxa7, Hoxa9, Hoxa10 and 217 
other Hoxb and Hoxc genes52,53. Likewise, Cdx compound deficient zebrafish and 218 
murine ESCs showed dysregulation of the embryonic hematopoietic progenitors as 219 
well as impaired expression of Hox genes54,55.  However, it has been shown that Cdxs 220 
are not essential for normal hematopoiesis in adult mice. For example, Cdx4 deficient 221 
mice showed minimal hematopoietic defects though it is highly expressed in wild type 222 
myeloid progenitor cells56. In addition, human CDX2 is not expressed in normal 223 
HSCs, or in myeloid, B-cell, or T-cell progenitors57-59. 224 
2.4 HOX downstream target genes in hematopoietic cells 225 
The mechanism by which HOX genes regulate hematopoiesis is not yet fully 226 
understood. However, genome wide analyses after experimentally induced changes in 227 
HOX gene expression have identified some potential downstream targets. Amongst 228 
these are the HOX genes themselves, some of which have been shown to auto-activate 229 
their own expression or to cross regulate their neighbours, or their co-factors. HOXA9, 230 
HOXA10 and HOXB4 are the most comprehensively studied genes in this respect 231 
because of their key roles in normal hematopoiesis and leukemia. It is particularly 232 
noteworthy that HOXA9 positively regulates the transcription of other HOX genes 233 
including HOXA7 and HOXA10 and its cofactors PBX3 and MEIS160. A summary of 234 
HOX downstream target genes is presented in table 2.   235 
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As described above, HOXA9 is a key regulator of hematopoiesis and behaves 236 
as an oncogene in leukemia. It is therefore unsurprising that it activates the 237 
transcription of genes known to regulate cell proliferation and survival. For example, 238 
Hoxa9 directly activates the Pim1 gene, the product of which enhances proliferation 239 
by activating c-Myb, and also exerts an anti-apoptotic effect by phosphorylating and 240 
inactivating the BAD protein61,62. C-Myb has also been identified as an indirect 241 
transcriptional target of Hoxa9-Meis1 that mediates transformation in Mll-Enl 242 
leukemia63. Other HOXA9 targets include the oncogene ID2 which is up regulated, 243 
and BIM, which encodes an apoptotic factor and is down regulated64. HOXA9 also 244 
activates the CYBB gene, which encodes Gp91phox (a phagocyte respiratory burst 245 
oxidase protein) and is expressed in differentiated myeloid cells65. In mice, Hoxa9 has 246 
been shown to directly activate the transcription of the Flt3 gene, which is associated 247 
with an unfavourable prognosis of AML66, and it also regulates its own cofactor, 248 
Meis1, through binding to Meis1 upstream regulator genes cerb1 and pknox167. More 249 
proliferative genes have been recently identified as downstream targets for Hoxa9 250 
including Camk2d, Cdk6, Erg, Etv6, Flt3, Foxp1, Gfi1, Kit, Lck, Lmo2, Myb and 251 
Sox468. In the same study, it was shown that Hoxa9 down regulates differentiation and 252 
inflammation genes including Ifit1, Tlr4, Ccl3, Ccl4, Csf2rb, Ifngr1, Runx1, Cd28 and 253 
Cd33. The fusion protein NUP98-HOXA9 has been found to stimulate the 254 
proliferation of HSCs by activating the expression of other homeobox genes including 255 
HOXA9, HOXA7, MEIS1 and PBX3. It also up regulates a number of leukemogenic 256 
transcription factors including EVI1 and MEF2C, and receptor tyrosine kinases 257 
including FLT3 and KIT69. 258 
It is also of note that there are both overlapping opposing functions between 259 
the closely related HOXA9 and HOXA10 transcription factors. For example, in a 260 
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similar manner to Hoxa9, Hoxa10 activates the expression of proliferative genes that 261 
result in myeloid progenitor expansion such as Itgb3, Hif, Tgfβ2 and Fgf2 by direct 262 
binding to their promoters70-73. HOXA10 also activates the transcription of anti-263 
apoptotic genes such as DUSP4, which encodes mitogen-activated protein kinase 2 264 
(MPK2). MPK2 in turn prevents cell death by down regulating JNK and p36 Map-265 
kinase74. Hoxa10 decreases erythroid differentiation and megakaryopoiesis by 266 
activating Hoxa5 and inactivating Gata-1, respectively70, and it also induces Cdx4 267 
expression in myeloid cells75. 268 
Unlike HOXA9, HOXA10 can also exert anti-proliferative effects. For 269 
example, in cooperation with its trimeric cofactors, HOXA10 induces P21 270 
transcription leading to cell cycle arrest and differentiation76. It also represses CYBB 271 
transcription77, thereby acting in an opposing manner to HOXA9. In a fusion form 272 
with Nup98, Hoxa10 activates more than 400 genes including the self-renewal genes 273 
Flt3, Prnp, Hlf, Jag278.   274 
Many HOXB4 target genes have also been identified in three recent studies79-275 
81. Overexpression of Hoxb4 resulted in transcriptional up regulation of Meis1, Dntt, 276 
Hlf, Sox4 and Runx2, whilst it down regulated the transcription of lymphoid specific 277 
genes, such as B220, and myeloid specific genes, such as Hmbs79. Some HOXB4 278 
targets seem to vary in a context dependent manner, for example it has been found to 279 
down regulate the transcription of C-MYC in the HL-60 cell line leading to cell 280 
differentiation82, whilst it activates c-Myc transcription in murine BM cells83. As with 281 
HOXA9, Hoxb4 activates the transcription of its neighbouring genes, Hoxb2, Hoxb3 282 
and Hoxb542. Hoxb4 also activates the AP-1 complex members Fra-1 and Jun-B 283 
which leads in turn to an increase in the level of cyclin-D1 and a decrease in the level 284 
of c-Fos transcription, thereby increasing the proliferation capacity of HSCs84.  285 
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3 The role of HOX genes in acute leukemia 286 
Numerous studies have now shown that HOX genes can promote the 287 
development of AML by forming chimeric fusions with other genes, but more recent 288 
work has also shown that their miss-expression, in particular their overexpression, is 289 
also important in the formation of malignancy. 290 
3.1 HOX fusion proteins 291 
One of the most frequent fusion partners for HOX genes is nucleoporin 98 292 
(NUP98), a member of the nuclear pore family (Figure 2). It is localized in the 293 
nuclear membrane and functions as a selective transporter for RNA and proteins 294 
between the nucleus and cytoplasm. NUP98-HOX fusion proteins have been reported 295 
in AML and other leukemias. In AML, NUP98-HOXA9 is associated with a 296 
t(7;11)(p15;p15) translocation85,86. There are eight other HOX genes that can be fused 297 
with NUP98, including HOXA11 and HOXA1387,88, HOXD11 and HOXD1389,90, and 298 
HOXC1391. Thus only the 5’ most members of each HOX complex have been 299 
documented to be fused with NUP98 in AML. However, Hoxb3 has been shown to be 300 
a potential leukemogenic partner with Nup9892, suggesting that the ability to be a 301 
fusion NUP98 partner is not limited to the 5’ most HOX genes. 302 
Nup98-Hox fusion proteins result in AML with a long latency, around 11-12 303 
months. However, this latency can be reduced to two months by co-overexpression of 304 
the Hox cofactor Meis1 and the receptor tyrosine kinase Flt393-95. FLT3 has an 305 
essential role in the regulation of early hematopoietic progenitors growth, and causes 306 
increased and uncontrolled self-renewal of these cells through a FLT3 ligand-307 
independent pathway96. 308 
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3.2 HOX overexpression in AML 309 
HOX genes may also be indirectly involved in AML through chromosomal 310 
rearrangements that involve their upstream regulators, such as MLL. MLL fusion 311 
proteins constitute about 10% of therapy related AML (t-AML) and 3% of de novo 312 
AML97. There are more than 64 translocation partner genes (TPG) that fuse with the 313 
MLL N-terminus98. Normally, Mll positively regulates the transcription of Hox genes 314 
by maintaining their expression through direct binding to a proximal promoter 315 
region99. MLL fusion proteins activate HOX gene transcription more efficiently than 316 
MLL alone97, especially the 5’ most members of the HOXA cluster, together with 317 
their co-activator MEIS1. As a consequence myeloid differentiation is blocked and 318 
proliferation is enhanced. Consistent with this proposed mechanism, it has been 319 
reported that MLL-AF9, like NUP98-HOXA9, leads to a block in erythroid/myeloid 320 
maturation and to erythroid hyperplasia100, and the Mll-Enl fusion protein requires 321 
Hoxa7 and Hoxa9 for efficient immortalization of myeloid precursor cells101. 322 
Conversely, a number of studies demonstrated that the expression of HOXA genes is 323 
not crucial for MLL leukemogenesis, yet their expression affects disease phenotype. 324 
For instance, Hoxa7 and Hoxa9 influence AML latency and phenotype; yet they are 325 
not essential to initiate Mll-Gas7 mediated leukemogenesis46. Furthermore, 326 
suppression of HOXA9 expression in cells with a chimeric MLL-AF9 gene reduces 327 
the survival of leukemic cells and changes the disease phenotype, but it does not 328 
affect AML initiation60.  329 
The dysregulation of another regulator of HOX genes, the CDX gene family, 330 
has also been shown to drive the development of AML. CDX2 is expressed in the 331 
majority of AML cases (90%), but not in normal adult hematopoiesis, and Cdx2 332 
elevated expression leads to AML with only a short latency period57. In contrast, the 333 
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closely related CDX4 gene is expressed in 25% of AML cases, and in normal adult 334 
hematopoiesis, and Cdx4 overexpression in murine whole bone marrow results in 335 
AML but only with a long latency period102. This latency can be accelerated in mice 336 
through cooperation of Meis1 which results in the overexpression of a number of Hox 337 
genes including Hoxa6, Hoxa7, Hoxa9, Hoxb4, Hoxb8 and Hoxc6103. Cdx2 expression 338 
alone is sufficient to drive the up regulation of a related set of HOX genes58, 339 
demonstrating the importance of the Cdx family in the dysregulation of Hox genes 340 
during AML.  341 
 The dysregulation of HOX gene expression is also associated with the 342 
nucleophosmin 1 (NPM1) mutation. NPM1 is a chaperone protein that shuttles 343 
between the nucleus and cytoplasm, although its predominant localization is in the 344 
nucleus104. NPM1 has a crucial role in several biological processes, such as ribosome 345 
biogenesis, genomic stability and cell cycle progression. In adult AML, NPM1 346 
mutation is the most common genetic aberration, reported in about 35% of all adult 347 
AML and approximately in 45% to 55% of normal karyotype AML (NK-AML)105-107. 348 
In pediatric AML, NPM1 mutations are significantly less common, occurring in 8-349 
10% of cases, and in about a quarter of normal karyotype cases108,109. The relocation 350 
of NPM1 into the cytoplasm (NPMc+) occurs only in AML110. This relocation causes 351 
up regulation of a number of HOX genes, some of which are similar to those seen in 352 
AML initiated by a MLL chimeric gene fusion, whilst some are distinct. Thus for 353 
example HOXA4, HOXA6, HOXA7, HOXA9, HOXB9 and MEIS1 are overexpressed 354 
in both contexts, whilst HOXB2, HOXB3, HOXB5, HOXB6 and HOXD4 are up 355 
regulated in NPMc+ AML only111. It has been reported that activation of a humanized 356 
Npm1 allele led to overexpression of Hoxa5, Hoxa7, Hoxa9 and Hoxa10, induction of 357 
HSC self-renewal and the expansion of myelopoiesis112. The exact mechanism of the 358 
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association between the NPM1 mutation and the up regulation of HOX genes is still 359 
unclear. A possible explanation is that NPM1 directly disturbs the expression of HOX 360 
genes, or alternatively, that NPM1 mutations arrest the differentiation of early 361 
hematopoietic progenitors in which HOX expression is up regulated104.  362 
 363 
3.3 HOX gene dysregulation in Acute Lymphoid Leukemia (ALL) 364 
The dysregulation of HOX genes has also been reported in ALL including both 365 
B- and T-precursor ALL (B- ALL and T-ALL), especially when MLL translocations 366 
(MLL-t ALL) are involved. For example, human HOXA9, HOXA10 and HOXC6, and 367 
their cofactor MEIS1 were up regulated in both MLL-ENL T-ALL and MLL B-368 
ALL113. Human HOXA9 and MEIS1, and murine Hoxa5, Hoxa9 and Meis1 were 369 
likewise up regulated in MLL-AF4 B-ALL114,115. A common signature of MLL 370 
rearrangements in AML and ALL is the overexpression of HOXA genes including 371 
HOXA3, HOXA5, HOXA7, HOXA9 and HOXA10116. Additionally, HOX genes can be 372 
involved in T-ALL through other translocations such as CALM-AF10 T-ALL where 373 
human HOXA5, HOXA9, HOXA10 and MEIS1 are overexpressed117. HOXA proteins 374 
can also form chimeric fusion proteins with T cell receptor (HOXA-TCR) in T-ALL 375 
which results in the global overexpression of HOXA genes118,119. Surprisingly, the 376 
aberrant expression of CDX2 in ALL, an upstream regulator of HOX genes, is not 377 
correlated with HOX gene dysregulation120.  378 
3.4 HOX genes as prognostic markers 379 
HOX gene expression has become an important prognostic factor in AML. 380 
Overexpression of HOX genes is associated with an intermediate/ unfavorable 381 
  17
cytogenetic subset of AML.  For example, among 6817 genes that have been 382 
investigated in AML patients, the single gene correlated with the worst outcome and 383 
relapse of disease as well as short survival was HOXA9121.  Correspondingly, low 384 
HOXA9 expression was found to correlate with the best outcome and response to 385 
therapy122. It is also noteworthy that low expression of HOXA4 and MEIS1 are also 386 
favorable predictors for AML patient outcome123. The global levels of HOX 387 
expression also seem to reflect the outcome of disease, possibly reflecting the 388 
functional redundancy exhibited by many of the HOX genes. Thus the highest levels 389 
of HOX genes are seen in FLT3 mutation cases, which have unfavorable outcomes, 390 
and generally the HOX genes are expressed only at a very low level in favorable 391 
subsets of AML.  392 
Future directions 393 
Although recent work has established the importance of HOX genes in the 394 
development of AML, it is still not clear exactly what the functions of these genes are 395 
beyond a general inhibition of differentiation and an increase in cell proliferation. 396 
This lack of precise mechanistic knowledge for individual HOX genes may be due to 397 
the functional redundancy showed by many members of this family, making the 398 
knock-down of single HOX genes generally difficult to interpret, and it may also help 399 
to explain the contrast in gene knock-in and knock-out results. In myeloma and some 400 
solid malignancies this has been addressed by targeting the HOX genes as a group by 401 
antagonizing their interactions with the PBX co-factor using the peptide inhibitor 402 
HXR9124-128. A similar approach may be useful in AML for addressing redundant 403 
functions of HOX genes. HXR9 is cytotoxic to cells, predominantly through the 404 
induction of apoptosis, which in turn depends upon a rapid increase in expression of 405 
cFos124-129. It seems likely that AML would also be sensitive to killing by HXR9, and 406 
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indeed it may be that the HOX genes could represent a useful therapeutic target, 407 
especially in AMLs that show high levels of HOX expression and a correspondingly 408 
poor prognosis. 409 
 410 
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 Figure Legends 854 
Figure 1: A schematic structure of clustered HOX genes. The 39 HOX genes are 855 
located on four different chromosomes. Homology of human HOX genes HOX-C 856 
to Drosophila HOM-C genes is shown by colours. Blank squares show missing 857 
genes.   858 
Figure 2: Structures of AbdB HOX, NUP98 and the predictive fusion protein 859 
NUP98-HOX. A) A general structure of AbdB HOX (9-13) proteins that have been 860 
reported to fuse with NUP98. B) Structure of normal NUP98 protein. C) Structure 861 
of predictive NUP98-HOX fusion protein. This fusion eliminates MD and RBD 862 
from AbdB and NUP98, respectively. The arrows represent the breakpoints. MD: 863 
MEIS domain, PM: Pbx motif, H: hexapeptide, HD: homeodomain, FG: 864 
phenylalanine-glycine, GLEBS: gle2p-binding-like motif, RBD: RNA binding 865 
domain. 866 
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Table 2: A summary of mammalian HOX target genes.  868 
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Table 1: HOX gene studies 
HOX gene Gain of function Loss of function Species References 
HOXA5 ↑myeloid progenitors and 
block erythroid 
differentiation. 
↑erythroid progenitors and 
↓myelomonocytic cells.  
Human 33,34  
Hoxa7  ↓ MEP, reticulocytosis and 
thrombocytopenia. 
Mouse 46 
Hoxa9 ↑HSCs expansion and 
myeloid progenitor 
proliferation. 
Block erythroid 
differentiation and ↓ pre B-
cell differentiation. 
↓↓CMP, GMP, CLP, lymphoid 
precursors, repopulating ability 
and ↓ spleen cellularity and 
size.  
Mouse 36,37,46,47
HOXA10 ↑↑ blast cells and 
myelopoiesis, ↓ B cell 
differentiation and block 
erythroid differentiation. 
 Human 35 
Hoxb3 Block B and T cell 
differentiation and a delay 
in myeloid precursor 
proliferation. 
↓↓ B cell progenitors and bone 
marrow cellularity.  
Mouse 31,44 
HOXB4/ 
Hoxb4 
↑↑ HSCs expansion.  ↓↓ Hematopoietic organs 
cellularity and size, ↓ HSCs 
and HPs and ↑ Hoxb genes. 
Human / Mouse 38,39,42,43
Hoxb3/b4  ↓↓ HSCs and HPs.   Mouse 45 
Hoxb6 ↑HSCs expansion and 
myeloid precursor 
proliferation. 
 ↓ erythropoiesis and 
lymphopoiesis.  
 ↑ Early erythroid progenitors. Mouse 30,48 
Hoxc3  ↓ erythroid progenitors.  Mouse 49 
HOXC4 ↑ early and committed 
myeloid and erythroid 
progenitors. 
 Human 32 
Hoxc8  ↓↓ erythroid, granulocyte and 
macrophage colony formation 
potential.  
Mouse 50 
 
 
 
 
 
 
Table 2: A summary of mammalian HOX target genes.  
HOX protein Targets of transcriptional activation Targets of transcriptional 
repression 
Species References 
HOXA9/ Hoxa9 Pim1, ID2, CYBB, HOXA7, HOXA10, 
PBX3 and MEIS1/ Flt3, Cerb1, Pknox1, 
Camk2d, Cdk6, Erg, Etv6, Foxp1, Gfi1, 
Kit, Lck, Lmo2, Myb and Sox4.  
BIM/ Itfi1, Tlr4, Ccl3, Ccl4, 
Csf2rb, Ifngr1, Runx1, 
Cd28, and Cd33. 
Human/ Mouse 60,61,64-68
Hoxa9-Meis1 c-Myb.  Mouse 63
NUP98-HOXA9 HOXA7, HOXA9, MEIS1, PBX3, EVI1, 
MEF2C, FLT3 and KIT. 
 Human 69
HOXA10/ 
Hoxa10 
P21 and DUSP4/ Itgb3, Hlf, Tgfβ2, Fgf2, 
Hoxa5, and Cdx4. 
CYBB/ Gata1. Human /  Mouse 70,73-77
Nup98-Hoxa10 Flt3, Prnp, Hlf and Jag2.   Mouse 78
HOXB4/ Hoxb4 Meis1, Dntt, Hlf, Sox4, Runx2, and C-myc/ 
Hoxb2, Hoxb3, Hoxb5, Fra-1 and JunB.    
B220 and  HMBS/ C-MYC. Human / Mouse 42,79,82-84
 
 
 
 
